SCHEMBL30989804

SCHEMBL30989804

COc1nccc(Cl)c1C(=O)N(C)Cc1ccc(F)cc1F

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 3/20 0.45
▸ GPR6 P46095 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ PIK3C3 Q8NEB9 1/20 0.37
▸ P2RX7 Q99572 1/20 0.36
▸ TACR1 P25103 1/20 0.36
▸ KDM5A P29375 1/20 0.36
▸ KDM4C Q9H3R0 1/20 0.36
▸ KDM5B Q9UGL1 1/20 0.36
▸ TAS2R14 Q9NYV8 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30989849 0.79 HSD17B13 (0.46) GPR6LMNAALDH1A1L3MBTL1GAA
SCHEMBL30989921 0.78 RIPK1 (0.45) RIPK1GPR6ALDH1A1L3MBTL1GAA
SCHEMBL30989936 0.76 RIPK1 (0.47) RIPK1GPR6ALDH1A1L3MBTL1GAA
SCHEMBL30989976 0.76 RIPK1 (0.46) RIPK1GPR6ALDH1A1L3MBTL1GAA
SCHEMBL30989901 0.75 RIPK1 (0.46) RIPK1GPR6ALDH1A1L3MBTL1GAA
SCHEMBL5644735 0.71 RIPK1 (0.54) RIPK1ALDH1A1GAAP2RX7MAOB
SCHEMBL30989925 0.69 RIPK1 (0.42) RIPK1GPR6L3MBTL1HTT
SCHEMBL5644473 0.69 RIPK1 (0.51) RIPK1LMNAALDH1A1GAAHTT
SCHEMBL5647030 0.68 KMT2A (0.58) RIPK1
SCHEMBL3964632 0.68 RIPK1 (0.59) RIPK1ALDH1A1HTTKDM4EMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024095003-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO disclosed
Send feedback